IN2013MU01468A - - Google Patents
Info
- Publication number
- IN2013MU01468A IN2013MU01468A IN1468MU2013A IN2013MU01468A IN 2013MU01468 A IN2013MU01468 A IN 2013MU01468A IN 1468MU2013 A IN1468MU2013 A IN 1468MU2013A IN 2013MU01468 A IN2013MU01468 A IN 2013MU01468A
- Authority
- IN
- India
- Prior art keywords
- compound
- formula
- fatty liver
- nonalcoholic
- liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein 'R' is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MA38385A MA38385A1 (en) | 2013-04-22 | 2013-06-25 | New composition for non-alcoholic fatty liver disease (nafld) |
PCT/IN2013/000391 WO2014174524A1 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
MX2015010769A MX346943B (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld). |
US14/782,609 US20160166539A1 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
GEAP201313941A GEP201706663B (en) | 2013-04-22 | 2013-06-25 | Novel composition for nonalcoholic fatty liver disease (nafld |
JP2016505927A JP6246895B2 (en) | 2013-04-22 | 2013-06-25 | Novel composition for non-alcoholic fatty liver disease (NAFLD) |
KR1020157024370A KR101617812B1 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease |
CN201380075905.9A CN105377246B (en) | 2013-04-22 | 2013-06-25 | For non-alcohol fatty liver (NAFLD) new compositions |
AP2015008674A AP2015008674A0 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (NAFLD) |
IN1468MU2013 IN2013MU01468A (en) | 2013-04-22 | 2013-06-25 | |
AU2013387996A AU2013387996B2 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (NAFLD) |
MYPI2015002026A MY180160A (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
UAA201509744A UA114360C2 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
EA201592020A EA201592020A1 (en) | 2013-04-22 | 2013-06-25 | NEW COMPOSITION FOR NONALCOHOLIC FATIAL LIVER DISEASE (NAFLD) |
CA2900435A CA2900435C (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
BR112015020600A BR112015020600A2 (en) | 2013-04-22 | 2013-06-25 | pharmaceutical composition, method for treating and / or ameliorating non-alcoholic liver fat disease and use of the composition |
SG11201506218UA SG11201506218UA (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
EP13767126.9A EP2988736A1 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
IL240183A IL240183A (en) | 2013-04-22 | 2015-07-28 | Composition for nonalcoholic fatty liver disease (nafld) |
PH12015501795A PH12015501795A1 (en) | 2013-04-22 | 2015-08-14 | A novel composition for nonalcoholic fatty liver disease (nafld) |
HK16103017.5A HK1214968A1 (en) | 2013-04-22 | 2016-03-15 | A novel composition for nonalcoholic fatty liver disease (nafld) (nafld) |
IL247231A IL247231A (en) | 2013-04-22 | 2016-08-11 | Composition for treating non-alcoholic fatty liver disease (nafld) |
US15/343,859 US9814697B2 (en) | 2013-04-22 | 2016-11-04 | Composition for nonalcoholic fatty liver disease (NAFLD) |
US15/801,738 US20180185330A1 (en) | 2013-04-22 | 2017-11-02 | Novel composition for nonalcoholic fatty liver disease (nafld) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1468MU2013 IN2013MU01468A (en) | 2013-04-22 | 2013-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2013MU01468A true IN2013MU01468A (en) | 2015-04-17 |
Family
ID=49253372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1468MU2013 IN2013MU01468A (en) | 2013-04-22 | 2013-06-25 |
Country Status (21)
Country | Link |
---|---|
US (3) | US20160166539A1 (en) |
EP (1) | EP2988736A1 (en) |
JP (1) | JP6246895B2 (en) |
KR (1) | KR101617812B1 (en) |
CN (1) | CN105377246B (en) |
AP (1) | AP2015008674A0 (en) |
AU (1) | AU2013387996B2 (en) |
BR (1) | BR112015020600A2 (en) |
CA (1) | CA2900435C (en) |
EA (1) | EA201592020A1 (en) |
GE (1) | GEP201706663B (en) |
HK (1) | HK1214968A1 (en) |
IL (2) | IL240183A (en) |
IN (1) | IN2013MU01468A (en) |
MA (1) | MA38385A1 (en) |
MX (1) | MX346943B (en) |
MY (1) | MY180160A (en) |
PH (1) | PH12015501795A1 (en) |
SG (1) | SG11201506218UA (en) |
UA (1) | UA114360C2 (en) |
WO (1) | WO2014174524A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA110813C2 (en) | 2011-01-31 | 2016-02-25 | Каділа Хелткере Лімітед | Treatment of lipodystrophy |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
CN105377246B (en) | 2013-04-22 | 2018-03-20 | 卡迪拉保健有限公司 | For non-alcohol fatty liver (NAFLD) new compositions |
WO2014195967A2 (en) | 2013-05-30 | 2014-12-11 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
TW201513857A (en) | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | Synergistic compositions |
IN2013MU02470A (en) * | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
ES2894261T3 (en) | 2016-12-09 | 2022-02-14 | Cadila Healthcare Ltd | Treatment of primary biliary cholangitis |
ES2927019T3 (en) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Therapeutic combinations for the treatment of liver diseases |
GB201710229D0 (en) * | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
TWI814744B (en) * | 2017-10-06 | 2023-09-11 | 美商基利科學股份有限公司 | Combination therapy comprising an acc inhibitor |
CN109675016A (en) * | 2017-10-18 | 2019-04-26 | 上海贺普药业股份有限公司 | The therapeutic agent of non-alcohol fatty liver |
CN110934866B (en) * | 2018-09-25 | 2023-12-01 | 深圳微芯生物科技股份有限公司 | Use of sitagliptin carboxylic acids and related compounds |
US20220071954A1 (en) * | 2018-12-18 | 2022-03-10 | Cadila Healthcare Limited | Saroglitazar for the treatment of hepatocellular carcinoma |
US20220175721A1 (en) * | 2019-02-13 | 2022-06-09 | Cadila Healthcare Limited | Treatment for polycystic ovarian syndrome (pcos) |
US20220378786A1 (en) * | 2021-05-21 | 2022-12-01 | HepQuant, LLC | Methods of defining functional change and slowing progression in chronic liver disease |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (en) | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
NZ253742A (en) | 1992-07-03 | 1997-06-24 | Smithkline Beecham Plc | Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions |
GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
US5387613A (en) | 1993-07-23 | 1995-02-07 | Ribogene, Inc. | Treatment of tachyarrhythmias of supraventricular origin |
GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
BR9508468A (en) | 1994-07-29 | 1997-11-25 | Smithkline Beecham Plc | Compound process for the preparation of the same pharmaceutical composition processes for the treatment and / or prophylaxis of hyperglycemia in a human or non-human mammal and for the treatment of hyperlipidemia hypertension cardiovascular disease some eating disorders the treatment and / or prophylaxis of kidney disease prevention revers o stabilization or retardation of microalbuminuria progression in a human or non-human mammal use of the compound and intermediate compound |
TW480262B (en) | 1995-04-28 | 2002-03-21 | Daiichi Seiyaku Co | A taxol derivative having an antitumor activity and a pharmaceutical composition comprising the same |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US6130214A (en) | 1997-10-27 | 2000-10-10 | Dr. Reddy's Research Foundation | Benzothiazin and benzoxazin derivatives; their preparation and uses |
CN1208326C (en) | 1998-04-23 | 2005-06-29 | 雷迪实验室有限公司 | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
CN100357281C (en) | 1998-05-27 | 2007-12-26 | 雷迪实验室有限公司 | Bicyclic compounds, process for their preparation and pharmaceutical composition containing them |
AU6325599A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
AU6325799A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
AU6325899A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
CO5150173A1 (en) | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
CA2397828C (en) | 2000-01-19 | 2007-09-04 | Cadila Healthcare Ltd. | Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
AU2001286163A1 (en) | 2000-09-22 | 2002-04-02 | Dr. Reddy's Research Foundation | An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US6987123B2 (en) * | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
JP4261546B2 (en) | 2003-09-26 | 2009-04-30 | 三菱レイヨン株式会社 | Electrophoresis apparatus and electrophoresis method |
CN102134229B (en) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors |
AU2006292217A1 (en) * | 2005-09-19 | 2007-03-29 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
KR20090083338A (en) * | 2006-09-18 | 2009-08-03 | 알닐람 파마슈티칼스 인코포레이티드 | Rnai modulation of scap and therapeutic uses thereof |
JP2008184429A (en) * | 2007-01-30 | 2008-08-14 | Japan Health Science Foundation | Liver triglyceride concentration-lowering agent |
ES2681794T3 (en) | 2009-11-26 | 2018-09-17 | Genfit | Use of 1,3-diphenylprop-2-in-1-one derivatives to treat liver disorders |
WO2012051333A1 (en) | 2010-10-12 | 2012-04-19 | The Johns Hopkins University | Antitussive compositions comprising memantine |
UA110813C2 (en) | 2011-01-31 | 2016-02-25 | Каділа Хелткере Лімітед | Treatment of lipodystrophy |
CN105377246B (en) | 2013-04-22 | 2018-03-20 | 卡迪拉保健有限公司 | For non-alcohol fatty liver (NAFLD) new compositions |
WO2014195967A2 (en) | 2013-05-30 | 2014-12-11 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
TW201513857A (en) | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | Synergistic compositions |
IN2013MU02470A (en) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
IN2013MU02828A (en) | 2013-08-29 | 2015-07-03 | Cadila Healthcare Ltd | |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
-
2013
- 2013-06-25 CN CN201380075905.9A patent/CN105377246B/en active Active
- 2013-06-25 BR BR112015020600A patent/BR112015020600A2/en not_active IP Right Cessation
- 2013-06-25 KR KR1020157024370A patent/KR101617812B1/en active IP Right Grant
- 2013-06-25 MA MA38385A patent/MA38385A1/en unknown
- 2013-06-25 AP AP2015008674A patent/AP2015008674A0/en unknown
- 2013-06-25 CA CA2900435A patent/CA2900435C/en not_active Expired - Fee Related
- 2013-06-25 IN IN1468MU2013 patent/IN2013MU01468A/en unknown
- 2013-06-25 MX MX2015010769A patent/MX346943B/en active IP Right Grant
- 2013-06-25 UA UAA201509744A patent/UA114360C2/en unknown
- 2013-06-25 GE GEAP201313941A patent/GEP201706663B/en unknown
- 2013-06-25 SG SG11201506218UA patent/SG11201506218UA/en unknown
- 2013-06-25 WO PCT/IN2013/000391 patent/WO2014174524A1/en active Application Filing
- 2013-06-25 EA EA201592020A patent/EA201592020A1/en unknown
- 2013-06-25 MY MYPI2015002026A patent/MY180160A/en unknown
- 2013-06-25 AU AU2013387996A patent/AU2013387996B2/en not_active Ceased
- 2013-06-25 JP JP2016505927A patent/JP6246895B2/en active Active
- 2013-06-25 EP EP13767126.9A patent/EP2988736A1/en not_active Withdrawn
- 2013-06-25 US US14/782,609 patent/US20160166539A1/en not_active Abandoned
-
2015
- 2015-07-28 IL IL240183A patent/IL240183A/en not_active IP Right Cessation
- 2015-08-14 PH PH12015501795A patent/PH12015501795A1/en unknown
-
2016
- 2016-03-15 HK HK16103017.5A patent/HK1214968A1/en unknown
- 2016-08-11 IL IL247231A patent/IL247231A/en not_active IP Right Cessation
- 2016-11-04 US US15/343,859 patent/US9814697B2/en active Active
-
2017
- 2017-11-02 US US15/801,738 patent/US20180185330A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN105377246B (en) | 2018-03-20 |
MX2015010769A (en) | 2015-11-26 |
MA38385A1 (en) | 2017-09-29 |
CA2900435C (en) | 2017-02-14 |
MX346943B (en) | 2017-04-06 |
JP6246895B2 (en) | 2017-12-13 |
IL240183A (en) | 2016-08-31 |
GEP201706663B (en) | 2017-05-10 |
US20170087127A1 (en) | 2017-03-30 |
AU2013387996A1 (en) | 2015-09-24 |
US20160166539A1 (en) | 2016-06-16 |
EA201592020A1 (en) | 2016-05-31 |
IL240183A0 (en) | 2015-09-24 |
AU2013387996B2 (en) | 2015-12-10 |
US9814697B2 (en) | 2017-11-14 |
CA2900435A1 (en) | 2014-10-30 |
MY180160A (en) | 2020-11-23 |
KR101617812B1 (en) | 2016-05-03 |
JP2016515608A (en) | 2016-05-30 |
US20180185330A1 (en) | 2018-07-05 |
CN105377246A (en) | 2016-03-02 |
UA114360C2 (en) | 2017-05-25 |
IL247231A (en) | 2017-03-30 |
HK1214968A1 (en) | 2016-08-12 |
BR112015020600A2 (en) | 2017-07-18 |
PH12015501795A1 (en) | 2015-11-09 |
KR20150118990A (en) | 2015-10-23 |
WO2014174524A8 (en) | 2015-10-01 |
AP2015008674A0 (en) | 2015-08-31 |
EP2988736A1 (en) | 2016-03-02 |
SG11201506218UA (en) | 2015-09-29 |
WO2014174524A1 (en) | 2014-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501795A1 (en) | A novel composition for nonalcoholic fatty liver disease (nafld) | |
EA032971B1 (en) | Berberine and ursodeoxycholic acid salt and application thereof | |
MX360979B (en) | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. | |
NZ726366A (en) | Syk inhibitors | |
MX349159B (en) | Deuterated derivatives of ivacaftor. | |
MX365950B (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis. | |
MY178621A (en) | Deuterated cftr potentiators | |
EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
SG10201806854XA (en) | Compositions comprising 15-ohepa and methods of using the same | |
MX2015004771A (en) | Methods of treating cancer. | |
MX2014000130A (en) | Methods and compositions for inhibition of bone resorption. | |
SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
BR112013021566A2 (en) | compound of formula, or a pharmaceutically acceptable salt or adduct thereof and method of preventing and / or treating an individual comprising administering to said individual a therapeutically effective amount of a compound of formula | |
PH12016502352A1 (en) | Pharmaceutical composition | |
BR112016024020A2 (en) | pharmaceutical composition | |
MX2012012095A (en) | Thiazolidinedione analogues. | |
BR112019005456A2 (en) | pharmaceutical composition and method for treating nonalcoholic hepatic steatosis | |
MX2015012455A (en) | Method for the treatment of fatty liver disease. | |
MX2019002579A (en) | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver. | |
EA201291384A1 (en) | THERAPEUTIC AGENTS 976 | |
PH12016501553B1 (en) | Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations | |
NZ701995A (en) | Therapeutic biologic for treatment of hepatocellular carcinoma |